Twist Bioscience Corporation updated earnings guidance for the full fiscal year 2024. For the year, Total revenue is expected to be in the range of $288 million to $293 million, growth of 18% to 20%, Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range and Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
50.46 USD | -4.79% | +20.43% | +36.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.90% | 2.94B | |
+0.82% | 91.94B | |
-1.32% | 38.74B | |
-12.88% | 32.82B | |
+64.77% | 26.66B | |
-16.31% | 15.32B | |
-11.38% | 11.65B | |
+173.10% | 10.37B | |
-49.84% | 10.12B | |
+5.24% | 9.06B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation Updates Earnings Guidance for the Full Fiscal Year 2024